Linker Information
General Information of This Linker
| Linker ID |
LIN0RVQXQ
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Pip-Val-Cit linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
|
|
||||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
AMT-151 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05498597 | Clinical Status | Phase 1 | ||
| Clinical Description |
First-in-human, phase 1 study of AMT-151, an anti-folate receptor alpha antibody-drug conjugate, in patients with selected advanced solid tumours.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible patients (≥18 years) must have advanced ovarian, endometrial, lung, breast, pancreatic, or mesothelioma cancers that progressed after prior therapies, with measurable/non-measurable disease per RECIST 1.1, ECOG 0-1, and adequate organ function. Exclusions include prior Folate Receptor Alpha-targeted therapy, active CNS metastases, unresolved toxicities (>Grade 1), recent anticancer therapies/radiotherapy/surgery, transplant history, or significant comorbidities. WCBP require negative pregnancy tests.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05498597 | Clinical Status | PHASE1 | ||
| Clinical Description |
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
|
||||
| Primary Endpoint |
The study evaluates the Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) based on dose-limiting toxicities (DLTs) over 24 months, alongside assessing safety through incidence of adverse events graded by CTCAE v5.0.
|
||||
| Other Endpoint |
Efficacy outcomes include Objective Response Rate (ORR), Disease Control Rate (DCR), Progression-Free Survival (PFS), Time to Treatment Response (TTR), Duration of Response (DoR), and Overall Survival (OS), along with pharmacokinetic parameters (Cmax, AUC, t1/2, Tmax) and anti-drug antibody (ADA) concentrations, all measured over 24 months.
|
||||
References